News From the Journals

International Study Proposes Refined Staging System for Medullary Thyroid Cancer

November 19, 2026 By Wendy LaGrego 3 min read
Share Share via Email Share on Facebook Share on LinkedIn Share on X

According to findings from a multinational study reported by Shi et al in the Journal of Clinical Oncology , a refined staging system for medullary thyroid cancer (MTC) demonstrated improved prognostic discrimination compared with the American Joint Committee on Cancer (AJCC) 8th edition TNM staging system. The proposed system incorporates a revised classification of lymph node metastases and redistributes patients across stages to better reflect disease-specific survival.

Study Details

The retrospective study was conducted by the International Medullary Thyroid Cancer Staging Consortium and included 2,573 patients with histologically confirmed MTC treated at 43 centers across 15 countries between May 1977 and June 2025. The median age was 52 years (interquartile range [IQR] = 41–62 years), and median follow-up was 76.3 months (IQR = 37.3–121.0 months). Disease-specific survival was the primary endpoint. An independent cohort of 1,909 patients from the U.S. Surveillance, Epidemiology, and End Results (SEER) database was used for external validation.

The investigators first evaluated the prognostic significance of lymph node metastases in the superior mediastinum (level VII), proposing their reclassification from N1a to a new N1c category. They then assessed 116,284 possible stage-grouping combinations using multivariable Cox models, selecting the model with the lowest Akaike information criterion. Distant metastatic disease remained classified as stage IVC, while stages I through IVB were reorganized according to tumor and nodal characteristics. Prognostic performance was compared using adjusted hazard ratios (aHRs) and the concordance index (C-index).

Key Results

Level VII lymph node metastases were associated with significantly poorer disease-specific survival than other nodal categories. In the multinational cohort, 10-year disease-specific survival was 98.32% for N0 disease, 94.24% for N1a, 81.36% for N1b, and 68.37% for N1c ( P < .001). Similar trends were observed in the SEER cohort.

The proposed staging system demonstrated clearer separation of survival outcomes across disease stages. In the multinational cohort, 10-year disease-specific survival rates were 99.49%, 94.33%, 86.42%, and 60.63% for stages I through IV, respectively, compared with 99.17%, 98.63%, 95.89%, and 77.13% under AJCC TNM-8.

The revised system also reduced the proportion of patients classified as stage IV from 42.4% to 20.2% in the multinational cohort and from 27.7% to 20.4% in the SEER cohort. This redistribution primarily reflected the reassignment of patients with certain nodal metastases to earlier stages.

Compared with AJCC TNM-8, the proposed system showed a more consistent increase in disease-specific mortality risk across successive stages. With stage I as the reference, aHRs were 2.22 for stage II, 4.81 for stage III, and 15.75 for stage IV (all P ≤ .001).

Prognostic discrimination improved significantly in the multinational cohort, with the C-index increasing from 0.856 to 0.892 ( P < .001). In the SEER validation cohort, the C-index increased from 0.852 to 0.860, although this difference was not statistically significant ( P = .280).

The investigators concluded: “The proposed [medullary thyroid cancer] staging system confers an improved schema for prognostic stratification compared with AJCC TNM-8.”

Yu Wang, MD, PhD , of the Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China and the Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, is the corresponding author for the Journal of Clinical Oncology article.

DISCLOSURE : The study was supported by the Noncommunicable Chronic Diseases–National Science and Technology Major Project, the National Natural Science Foundation of China, and others. For full disclosures of the study authors, visit ascopubs.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.